Effects of pentoxifyllin and PentaglobinO on TNF and IL-6 production in septic patients.

Y. Mándi, G. Farkas, I. Ocsovszky

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Pentoxifylline inhibited the TNF production of purified human white blood cells and whole blood cultures stimulated either by LPS or by Staphylococcus aureus. PTX did not influence the CD14 expression. The in vitro TNF and IL-6-producing capacities of septic patients were higher than in the control group. Administration of PTX to septic patients resulted in the normalization of TNF synthesis and in a moderate decrease in IL-6 production. It also subsequently led to an improvement in the clinical status. A further improvement in APACHE II score could be achieved by administration of PentaglobinO (Biotest). The prevention of in vitro TNF production by PentaglobinO could be demonstrated involving the use of whole blood rather than purified lymphocytes. The level of soluble ICAM-1 in the serum of septic patients was significantly higher than in normal individuals, but it decreased following PTX and PentaglobinO therapy. It is presumed that PTX and PentaglobinO can antagonize cytokine production at different levels, resulting in synergistic action that is beneficial in the treatment of sepsis.

Original languageEnglish
Pages (from-to)301-308
Number of pages8
JournalActa Microbiologica et Immunologica Hungarica
Volume42
Issue number3
Publication statusPublished - 1995

Fingerprint

Interleukin-6
Pentoxifylline
APACHE
Intercellular Adhesion Molecule-1
Staphylococcus aureus
Sepsis
Leukocytes
Lymphocytes
Cytokines
Control Groups
Therapeutics
Serum
In Vitro Techniques
Blood Culture

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Medicine(all)
  • Microbiology

Cite this

Effects of pentoxifyllin and PentaglobinO on TNF and IL-6 production in septic patients. / Mándi, Y.; Farkas, G.; Ocsovszky, I.

In: Acta Microbiologica et Immunologica Hungarica, Vol. 42, No. 3, 1995, p. 301-308.

Research output: Contribution to journalArticle

@article{c5b828d5209049bd911c1ed5d9b577e4,
title = "Effects of pentoxifyllin and PentaglobinO on TNF and IL-6 production in septic patients.",
abstract = "Pentoxifylline inhibited the TNF production of purified human white blood cells and whole blood cultures stimulated either by LPS or by Staphylococcus aureus. PTX did not influence the CD14 expression. The in vitro TNF and IL-6-producing capacities of septic patients were higher than in the control group. Administration of PTX to septic patients resulted in the normalization of TNF synthesis and in a moderate decrease in IL-6 production. It also subsequently led to an improvement in the clinical status. A further improvement in APACHE II score could be achieved by administration of PentaglobinO (Biotest). The prevention of in vitro TNF production by PentaglobinO could be demonstrated involving the use of whole blood rather than purified lymphocytes. The level of soluble ICAM-1 in the serum of septic patients was significantly higher than in normal individuals, but it decreased following PTX and PentaglobinO therapy. It is presumed that PTX and PentaglobinO can antagonize cytokine production at different levels, resulting in synergistic action that is beneficial in the treatment of sepsis.",
author = "Y. M{\'a}ndi and G. Farkas and I. Ocsovszky",
year = "1995",
language = "English",
volume = "42",
pages = "301--308",
journal = "Acta Microbiologica et Immunologica Hungarica",
issn = "1217-8950",
publisher = "Akademiai Kiado",
number = "3",

}

TY - JOUR

T1 - Effects of pentoxifyllin and PentaglobinO on TNF and IL-6 production in septic patients.

AU - Mándi, Y.

AU - Farkas, G.

AU - Ocsovszky, I.

PY - 1995

Y1 - 1995

N2 - Pentoxifylline inhibited the TNF production of purified human white blood cells and whole blood cultures stimulated either by LPS or by Staphylococcus aureus. PTX did not influence the CD14 expression. The in vitro TNF and IL-6-producing capacities of septic patients were higher than in the control group. Administration of PTX to septic patients resulted in the normalization of TNF synthesis and in a moderate decrease in IL-6 production. It also subsequently led to an improvement in the clinical status. A further improvement in APACHE II score could be achieved by administration of PentaglobinO (Biotest). The prevention of in vitro TNF production by PentaglobinO could be demonstrated involving the use of whole blood rather than purified lymphocytes. The level of soluble ICAM-1 in the serum of septic patients was significantly higher than in normal individuals, but it decreased following PTX and PentaglobinO therapy. It is presumed that PTX and PentaglobinO can antagonize cytokine production at different levels, resulting in synergistic action that is beneficial in the treatment of sepsis.

AB - Pentoxifylline inhibited the TNF production of purified human white blood cells and whole blood cultures stimulated either by LPS or by Staphylococcus aureus. PTX did not influence the CD14 expression. The in vitro TNF and IL-6-producing capacities of septic patients were higher than in the control group. Administration of PTX to septic patients resulted in the normalization of TNF synthesis and in a moderate decrease in IL-6 production. It also subsequently led to an improvement in the clinical status. A further improvement in APACHE II score could be achieved by administration of PentaglobinO (Biotest). The prevention of in vitro TNF production by PentaglobinO could be demonstrated involving the use of whole blood rather than purified lymphocytes. The level of soluble ICAM-1 in the serum of septic patients was significantly higher than in normal individuals, but it decreased following PTX and PentaglobinO therapy. It is presumed that PTX and PentaglobinO can antagonize cytokine production at different levels, resulting in synergistic action that is beneficial in the treatment of sepsis.

UR - http://www.scopus.com/inward/record.url?scp=0029444875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029444875&partnerID=8YFLogxK

M3 - Article

C2 - 8548203

AN - SCOPUS:0029444875

VL - 42

SP - 301

EP - 308

JO - Acta Microbiologica et Immunologica Hungarica

JF - Acta Microbiologica et Immunologica Hungarica

SN - 1217-8950

IS - 3

ER -